Navigation Links
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
Date:11/10/2008

currently collaborating with UCSD in an ongoing phase IIa clinical study of cysteamine in NASH patients. Raptor plans to initiate a pivotal study of DR Cysteamine in cystinosis patients in 2009.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. We focus on underserved patient populations where we can have the greatest potential impact. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit http://www.raptorpharma.com.

About CHU d'Angers

The CHU d'Angers ("CHU"), a healthcare center and center of reference, research, and expertise, is a leader in treatment, teaching, research and prevention. CHU ensures quality patient services by reconciling patient care and medical innovation on a day to day basis. As one of the region's first healthcare players, CHU continues to maintain quality care.

With 5,500 employees across 50 clinical and biological departments, CHU encompasses all therapeutic, chirurgical and biological areas, including centers of reference and competency. 77,000 people are hospitalized in 1,459 beds and 300,000 consultations are performed annually at CHU by teams of physicians involved in hospital and teaching activities, whose performance is sustained by leading technical teams.

Dr
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...sia-FirstCall/--ChinaSkyOne,Medical,Inc.("ChinaSky...gfullyintegratedpharmaceuticalcompanydevelopingand...icofChina("PRC"),today,announcedthattheCompanyrece...lofPharmaceuticalandBiologicalProducts("ICPBP")exa...rHumanProstateSpecific,Antigen(ColloidalGold)andit...
(Date:11/25/2009)...--AccordingtoMillenniumResearchGroup(MRG),thegloba...enearly$3billionUSmarketfortraumafixationdeviceswi...itetherecenteconomicslowdown.MRG,s USMarketsforTra...inhighlydynamicoverthenextfiveyears,withcompetitor...vedsegmentsofthetraumafixationmarket,fuelingmarket...
(Date:11/25/2009)...URG,November25/PRNewswire/--,iThembaPharmaceutical...hattheyhavesignedacollaborativeagreementtojointlym...lasscomputationalchemistryandleaddiscoveryexpertis...demedicinaland,syntheticchemistrysupporttoprojects....iThembaPharmaceuticalsandPyxisDiscovery,alsoannou...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 1Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 2Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 1Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 2Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 4Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 5Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 6Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 7Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 8Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 9Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 10Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 11TeamStaff Inc To Announce Third Quarter Results 54190 1TeamStaff Inc To Announce Third Quarter Results 54190 2TeamStaff Inc To Announce Third Quarter Results 54190 3
(Date:11/25/2009)...EMERYVILLE,Calif.,Nov.25/PRNewswire-FirstCall/-- ...cedthatthecompanywillhosttwoinvestoreventsinDecemb...:00a.m.CT/10:00a.m.ET ,, Principalinvestigato...ibinrelapsedand/orrefractorymultiplemyeloma,asfeat...lMeetingandExpositioninNewOrleans,LA.Theteleconfer...
(Date:11/25/2009)...LOSANGELES,Nov.25/PRNewswire-USNewswire/--TheBlack...odetermineexecutiveleadershipfor2010. ,, Thenew...cialtiesinpublicpolicy,law,finance,governmenthealt...eBoardalsocomesfromawiderangeofpersonalbackgrounds...melivingwithHIVthemselves,andrepresentingmultiplea...
(Date:11/25/2009)...rtuitous discovery that grew out of a collaboratio...ntially offer hope to the nearly 10 million Americ... , Also known as hardening of the arteries, pe...culatory problem in which narrowed arteries reduce...red a red flag for vascular disease, heart attack ...
(Date:11/25/2009)... forgetfulness could lead mothers to overlook need... 25 (HealthDay News) -- A mother,s depression can ...ound. , Their six-month study of 262 black moth...others had more depressive symptoms had more frequ...h fewer depressive symptoms had less frequent asth...
(Date:11/25/2009)... LittleImprovementShownforthe4thStraightYear ,...day,LungCancerAlliance-Georgia(LCA-GA)issuedthe 4t...smentofprogressbeingmadeagainstthislethaldiseasein...ance(LCA),theonlynationalorganizationdedicatedexcl...ithoratriskforlungcancer. ,, (Logo: http://www....
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
...experts reported that women in India are gradually...d they comprise about 40 percent of India’s infect...e susceptible to HIV infection. Besides, gender di...n security unit, United Nations Development Fund f...
...entists have now found that women who skip their m...r methods are less likely to develop cancers// rel...vical cancer, uterine cancer, ovarian cancer. ...varian and endometrial cancers, says Professor Ian...
...ach may have some beneficial effects in fighting c...cancer have the potential to perform better with t...body’s immune system to recognize cancer tissues a...ity College London (UCL) have been able to place a...
... Cancer patients who actively use the internet to ... positive outlook, and are well aware of the possi...ried out by the Temple University and has been pub...eiterated that this is the first study that has so...
... referral management centres have been blamed for ...for surgery. These centres that dictate the where ...between the hospitals and GPs. Officials belonging...s are currently being managed by staff belonging t...
...st plastic surgeons to be greedier! Not satisfied ...splant on a French woman, plastic surgeons are hun...Reporting in the March issue of Plastic and Recons...dure of a full-face transplant. "For the fir...
Other Medicine News:Health News:Biologically Women Are More Vulnerable To HIV Infection 2Health News:Internet Research Fosters Confidence and Positivity in Cancer Patients 2Health News:Referral Schemes Blamed By GPs For Treatment Delay 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: